{
    "Trade/Device Name(s)": [
        "RapidBUP Test Strip",
        "RapidOXY Test Strip",
        "MICROMEDIC Drugs of Abuse Panel Test"
    ],
    "Submitter Information": "Rapid Diagnostics, Inc., a division of MP Biomedicals, LLC",
    "510(k) Number": "K051958",
    "Predicate Device Reference 510(k) Number(s)": [
        "K033566"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG"
    ],
    "Summary Letter Date": "June 15, 2006",
    "Summary Letter Received Date": "June 26, 2006",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Oxycodone",
        "Buprenorphine-3-beta-d-glucuronide"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [
        ""
    ],
    "Instrument(s)/Platform(s)": [
        ""
    ],
    "Method(s)/Technology(ies)": [
        "Immunochromatography"
    ],
    "Methodologies": [
        "Immunochemical reaction",
        "Competitive binding assay"
    ],
    "Submission Type(s)": [
        "Test Strip",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for MP RapidOXY and MP RapidBUP Test Strips for qualitative detection of oxycodone and buprenorphine metabolites in human urine using immunochromatography",
    "Indications for Use Summary": "Qualitative determination of oxycodone (cut-off 100 ng/ml) and buprenorphine-3-beta-d-glucuronide (cut-off 10 ng/ml) in human urine in point-of-care settings; provides preliminary results requiring confirmatory testing",
    "fda_folder": "Toxicology"
}